Arcus Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on May 23, 2024. The filing reports a significant clinical development event regarding the Company's Phase 1b/2 clinical trial, ARC-9.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements or performance metrics.
Material Changes and Clinical Update
- Event: An abstract containing data from an interim analysis of Cohort B of the ARC-9 trial was published on the American Society of Clinical Oncology (ASCO) website on May 23, 2024.
- Trial Details: Cohort B evaluates the combination of etrumadenant and zimberelimab with FOLFOX and bevacizumab versus regorafenib in patients with third-line metastatic colorectal cancer.
- Recognition: The abstract has been selected for an oral presentation at the 2024 ASCO Annual Meeting.
Outlook and Management Commentary
Management plans to issue a press release on June 2, 2024, to announce the full results of the interim analysis. The oral presentation is scheduled to occur on Sunday, June 2, 2024, during the ASCO Annual Meeting.
Investor Verification Checklist
- Verify the full text of the abstract attached as Exhibit 99.1 for specific efficacy and safety data points.
- Monitor the press release scheduled for June 2, 2024, for the complete interim analysis results.
- Confirm the oral presentation schedule at the 2024 ASCO Annual Meeting for potential live updates or Q&A sessions.